WINDSOR, England--(BUSINESS WIRE)--Celgene Limited--The National Institute for Health and Clinical Excellence (NICE) has issued new guidance, recommending the use of REVLIMID (lenalidomide), in combination with dexamethasone, for the treatment of relapsed/refractory multiple myeloma. According to the guidance, REVLIMID should be prescribed in patients who have received two or more prior therapies.1 In accordance with this guidance, REVLIMID, an oral treatment, will now be made available for prescription through primary care trusts in England and Wales.
